Skip to main content
Premium Trial:

Request an Annual Quote

Quark Subsidiary to Head Israeli RNAi Consortium


QBI, a wholly owned subsidiary of Quark Pharmaceuticals, will head an Israeli consortium of industry and academic collaborators focused on developing "novel genetic technologies in the field of RNAi," the company said in a filing with the US Securities and Exchange Commission last month.

According to Quark, the Israeli government will financially support the consortium, which will specifically develop technologies related to RNAi chemistry, including chemical modifications, basic siRNA structure, and molecular manufacture; formulations, including delivery methods; and analytical approaches to facilitate the discovery, as well as the preclinical and clinical development, of RNAi agents.

Quark noted in the filing, which was submitted to the SEC as part of the company's plan to go public in the US (GSN 10/7/2010), that "the intellectual properties and technologies developed by QBI in the consortium shall remain with QBI at all times."

Additional details were not available.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.